Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SUPN
#1833
Supernus Pharmaceuticals, Inc. - Common Stock
44.2
1
USD
+0.01%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+1.10%
Monthly Change
-12.37%
6 month change
-18.11%
Year Change
-18.13%
Previous Close
43.7
3
Open
44.2
1
Low
44.2
1
High
44.2
1
Volume
76
Markets
US Stock Market
Healthcare
Drug Manufacturers—Specialty & Generic
SUPN
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
Q1, 25
Q2, 25
Q3, 25
Q4, 25
Q1, 26
Q2, 26
Current
Key stats
Total common shares outstanding
55.99 M
56.07 M
57.34 M
57.58 M
58.04 M
58.13 M
58.13 M
Valuation ratios
Enterprise value
1.72 B
1.62 B
2.59 B
2.73 B
2.82 B
2.52 B
2.37 B
Price to earnings ratio
29.5
27.41
-140.56
-73.09
-101.35
-24.22
-22.86
Price to sales ratio
2.74
2.66
3.94
3.9
3.78
3.2
3.02
Price to cash flow ratio
11.14
9.46
37.47
59.28
35.68
139.84
131.97
Price to book ratio
0.45
0.43
0.64
2.64
0.69
0.63
0.59
Enterprise value to EBITDA ratio
11.11
11.2
53.43
93.35
76.18
-87.74
-82.45
Profitability ratios
Return on assets %
-0.01
0.02
-0.03
-0
-0
-0.04
-0.04
Return on equity %
-0.01
0.02
-0.04
-0
-0
-0.06
-0.06
Return on invested capital %
0.1
5.65
-16.17
-2.84
-1.06
-19.94
-19.94
Gross margin %
89.48
89.83
90.13
89.13
88.74
84.63
84.63
Operating margin %
-6.85
7.34
-31.35
-1.86
-4.01
-26.46
-26.46
EBITDA margin %
6.76
20.25
-18.44
9.96
8.57
-14.71
-14.71
Net margin %
-7.89
13.6
-23.49
-1.94
-1.1
-26.65
-26.65
Liquidity ratios
Quick ratio
2.26
2.43
1.47
1.57
1.66
1.77
1.77
Current ratio
2.44
2.58
1.8
1.9
1.96
2.08
2.08
Inventory turnover
0.3
0.38
0.18
0.21
0.21
0.31
0.31
Asset turnover
0.11
0.12
0.14
0.15
0.14
0.15
0.15
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.55
1.03
-1.09
0.35
1.15
-0.08
0.33
EBIT per share
-0.18
0.21
-1.07
-0.07
-0.14
-1
-2.28
EBITDA per share
0.18
0.59
-0.63
0.37
0.31
-0.55
-0.5
Total debt per share
—
—
—
—
—
—
—
Cash per share
2.07
2.55
2.68
2.28
3.21
3.1
3.1
Net current asset value per share
12.31
13.04
10.5
11.41
12.69
12.46
12.46
Tangible book value per share
18.45
18.78
5.43
6.51
7.05
7.62
7.62
Working capital per share
7.26
7.99
4.66
5.42
6.2
6.48
6.48
Book value per share
18.45
18.78
18.56
18.81
18.68
17.76
17.76
News
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
New Strong Buy Stocks for August 7th
Best Value Stocks to Buy for August 7th
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Stocks Settle Sharply Higher as Middle East Tensions Ease
Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript
Supernus And Indivior Merger: There May Be Some Skepticism, But I Have Faith In This Deal